Our objective was to perform an early target validation of the effects of a Nrf2 pathway activator, dimethyl fumarate, on the incidence of chronic diseases (T2D, CVD and CKD) in human populations prior to embarking on lengthy preclinical drug development initiatives in related indications. Here, NFE2L2 is linked to type 2 diabetes mellitus.